Hepatitis B virus (HBV) reactivation is commonly observed in individuals with chronic HBV infection undergoing antineoplastic drug therapy. Paclitaxel (PTX) treatment has been identified as a ...
Hepatitis B virus (HBV) reactivation is commonly observed in individuals with chronic HBV infection undergoing antineoplastic drug therapy. Paclitaxel (PTX) treatment has been identified as a ...
FDA regulatory momentum includes priority review and breakthrough therapy designation for a potential first-in-class CHB ...
Two cross-sectional, one validation cohort, and meta-analyses were used to explore the relationship between HBV replication and liver inflammation. Spearman analysis, multiple linear regression, and ...
PARIS — People with HIV and resolved HBV infection who switched from tenofovir-based antiretroviral therapy (ART) to tenofovir-sparing regimens did not see clinically meaningful hepatitis B virus (HBV ...
Some 254 million people live with a chronic hepatitis B (HBV) infection that is often asymptomatic for decades, only to emerge in an advanced stage of disease that turns to fatal cirrhosis or liver ...
An exclusive China launch collaboration positions CTTQ to lead importation, distribution, hospital access, and promotion, while GSK retains marketing authorization and oversight of regulatory, quality ...
C. elegans as a new animal model for treating HBV We are in the process of mapping and cloning the hids genes. We also initiated a large-scale drug screen in C. elegans to isolate compounds that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results